{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:50:05Z","timestamp":1648993805694},"reference-count":24,"publisher":"Japanese Association of Rural Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rural Med"],"published-print":{"date-parts":[[2021]]},"DOI":"10.2185\/jrm.2021-014","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T22:17:52Z","timestamp":1633040272000},"page":"250-255","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after          amrubicin monotherapy failure"],"prefix":"10.2185","volume":"16","author":[{"given":"Kohei","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sosuke","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kainan Hospital              Aichi Prefectural Welfare Federation of Agricultural Cooperatives,            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"995","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.               Gazdar              AF            ,               Bunn              PA            ,               Minna              JD            . Small-cell lung cancer: what we know, what we            need to know and the path forward. Nat Rev            Cancer 2017; 17:            725\u2013737.","DOI":"10.1038\/nrc.2017.87"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2.               Hansen              HH            . Management of small-cell cancer of the            lung. Lancet 1992; 339:            846\u2013849.","DOI":"10.1016\/0140-6736(92)90287-D"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3.               Farago              AF            ,               Keane              FK            . Current standards for clinical management of            small cell lung cancer. Transl Lung Cancer            Res 2018; 7: 69\u201379.","DOI":"10.21037\/tlcr.2018.01.16"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.               DiBonaventura              MD            ,               Shah-Manek              B            ,               Higginbottom              K            , et al. Adherence to recommended            clinical guidelines in extensive disease small-cell lung cancer across the US, Europe,            and Japan. Ther Clin Risk Manag 2019;            15: 355\u2013366.","DOI":"10.2147\/TCRM.S183216"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.               Kanda              Y            . Investigation of the freely available easy-to-use            software \u2018EZR\u2019 for medical statistics. Bone Marrow            Transplant 2013; 48:            452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.               Horita              N            ,               Yamamoto              M            ,               Sato              T            , et al. Amrubicin for relapsed            small-cell lung cancer: a systematic review and meta-analysis of 803            patients. Sci Rep 2016; 6:            18999.","DOI":"10.1038\/srep18999"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.               Jotte              R            ,               Conkling              P            ,               Reynolds              C            , et al. Randomized phase II trial of            single-agent amrubicin or topotecan as second-line treatment in patients with small-cell            lung cancer sensitive to first-line platinum-based chemotherapy.            J Clin Oncol 2011; 29:            287\u2013293.","DOI":"10.1200\/JCO.2010.29.8851"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.               von Pawel              J            ,               Jotte              R            ,               Spigel              DR            , et al. Randomized phase III trial of            amrubicin versus topotecan as second-line treatment for patients with small-cell lung            cancer. J Clin Oncol 2014;            32: 4012\u20134019.","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.               Inoue              A            ,               Sugawara              S            ,               Yamazaki              K            , et al. Randomized phase II trial            comparing amrubicin with topotecan in patients with previously treated small-cell lung            cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin            Oncol 2008; 26:            5401\u20135406.","DOI":"10.1200\/JCO.2008.18.1974"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.               von Pawel              J            ,               Schiller              JH            ,               Shepherd              FA            , et al. Topotecan versus            cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell            lung cancer. J Clin Oncol 1999;            17: 658\u2013667.","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.               Park              SH            ,               Cho              EK            ,               Kim              Y            , et al. Salvage treatment with            topotecan in patients with irinotecan-refractory small cell lung cancer.            Cancer Chemother Pharmacol 2008; 62:            1009\u20131014.","DOI":"10.1007\/s00280-008-0690-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.               Ogawara              M            ,               Negoro              S            ,               Nishiwaki              Y            , et al. Phase II study of topotecan            (TOP) for relapsed small cell lung cancer (SCLC). Lung            Cancer 2000; 29(Supple          1): 40.","DOI":"10.1016\/S0169-5002(00)80129-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.               Trigo              J            ,               Subbiah              V            ,               Besse              B            , et al. Lurbinectedin as second-line            treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2            basket trial. Lancet Oncol 2020;            21: 645\u2013654.","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.               Antonia              SJ            ,               L\u00f3pez-Martin              JA            ,               Bendell              J            , et al. Nivolumab alone and nivolumab            plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre,            open-label, phase 1\/2 trial. Lancet            Oncol 2016; 17:            883\u2013895.","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15.               Ready              NE            ,               Ott              PA            ,               Hellmann              MD            , et al. Nivolumab monotherapy and            Nivolumab plus Ipilimumab in recurrent small cell lung cancer: results from the            CheckMate 032 randomized cohort. J Thorac            Oncol 2020; 15:            426\u2013435.","DOI":"10.1016\/j.jtho.2019.10.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16.               Chung              HC            ,               Piha-Paul              SA            ,               Lopez-Martin              J            , et al. Pembrolizumab after two or            more lines of previous therapy in patients with recurrent or metastatic SCLC: results            from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac            Oncol 2020; 15:            618\u2013627.","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.               Smit              EF            ,               Fokkema              E            ,               Biesma              B            , et al. A phase II study of            paclitaxel in heavily pretreated patients with small-cell lung cancer.            Br J Cancer 1998; 77:            347\u2013351.","DOI":"10.1038\/bjc.1998.54"},{"key":"18","unstructured":"18.               Yamamoto              N            ,               Tsurutani              J            ,               Yoshimura              N            , et al. Phase II study of weekly            paclitaxel for relapsed and refractory small cell lung cancer.            Anticancer Res 2006;            26(1B): 777\u2013781."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19.               Smyth              JF            ,               Smith              IE            ,               Sessa              C            , et al. The Early Clinical Trials Group            of the EORTCActivity of docetaxel (Taxotere) in small cell            lung cancer. Eur J Cancer 1994;            30A: 1058\u20131060.","DOI":"10.1016\/0959-8049(94)90455-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.               Masuda              N            ,               Fukuoka              M            ,               Kusunoki              Y            , et al. CPT-11: a new derivative of            camptothecin for the treatment of refractory or relapsed small-cell lung            cancer. J Clin Oncol 1992;            10: 1225\u20131229.","DOI":"10.1200\/JCO.1992.10.8.1225"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21.               van der Lee              I            ,               Smit              EF            ,               van Putten              JW            , et al. Single-agent gemcitabine in            patients with resistant small-cell lung cancer. Ann            Oncol 2001; 12:            557\u2013561.","DOI":"10.1023\/A:1011104509759"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22.               Masters              GA            ,               Declerck              L            ,               Blanke              C            , et al. Eastern Cooperative Oncology            GroupPhase II trial of gemcitabine in refractory or            relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial            1597. J Clin Oncol 2003;            21: 1550\u20131555.","DOI":"10.1200\/JCO.2003.09.130"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23.               Sugiyama              K            ,               Kogure              Y            ,               Torii              A            , et al. Solvent-based paclitaxel or            nab-paclitaxel for heavily treated relapsed\/refractory small cell lung cancer:            Retrospective single-institution observational study. Medicine            (Baltimore) 2019; 98: e14758.","DOI":"10.1097\/MD.0000000000014758"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24.               Nakao              M            ,               Fujita              K            ,               Suzuki              Y            , et al. Nab-paclitaxel monotherapy            for relapsed small cell lung cancer: retrospective analysis and review.            Anticancer Res 2020; 40:            1579\u20131585.","DOI":"10.21873\/anticanres.14105"}],"container-title":["Journal of Rural Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jrm\/16\/4\/16_2021-014\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T05:07:26Z","timestamp":1633151246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jrm\/16\/4\/16_2021-014\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2185\/jrm.2021-014","relation":{},"ISSN":["1880-487X","1880-4888"],"issn-type":[{"value":"1880-487X","type":"print"},{"value":"1880-4888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"2021-014"}}